Epstein David R purchased $89K of AGMB
Epstein David R purchased 14,980 shares of AgomAb Therapeutics NV (AGMB) at an average of $5.92 ($5.75–$6.02) across 4 trades on 2026-11-13.
How this was made
The 30-second read
Why it matters
The filing provides fresh, primary information but the transaction size is modest, limiting trading relevance.
Market read
New insider purchase disclosed; low material impact on stock price.
What to watch
Potential upcoming clinical trial milestones that may have prompted the purchase.
Background
SEC Form 4 filing discloses a director's recent purchase of AGMB shares.
Ticker impact
Director Epstein purchased 14,980 shares at a weighted avg $5.92, increasing his stake to 54,980 shares.
slight upward pressure as market prices in insider confidence
The purchase is a primary Form 4 filing but the total value (~$89K) is trivial for a public biotech, so any price move is likely minimal.
Market effects
Minimal effect on biotech sector; typical insider activity.
Negligible impact on European markets.
Low relevance to global markets.
Counterpoint
The insider purchase could be a routine portfolio rebalancing rather than a confidence signal.
Key entities
- CompanyAgomAb Therapeutics NV
Biotech company listed on Nasdaq under ticker AGMB.
- InsiderEpstein David R
Director of AGMB who made the purchase.